|
1
|
Girard E, Nacher M, Bukasa-Kakamba J, Fahrasmane A, Adenis A, Massicard M, Drak Alsibai K, De Toffol B, Bekima R, Thelusme L, Okambabelle D, Demar M, Aurelus JM, Sabbah N. Vitamin D Deficiency in Patients with Diabetes in French Guiana: Epidemiology and Relation with Microvascular and Macrovascular Complications. Nutrients 2021; 13:nu13124302. [PMID: 34959854 PMCID: PMC8707589 DOI: 10.3390/nu13124302] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2021] [Revised: 11/24/2021] [Accepted: 11/25/2021] [Indexed: 01/12/2023] Open
Abstract
Vitamin D (VD) insufficiency is common among patients with diabetes in French Guiana. The study aimed to evaluate the prevalence of VD deficiency in the different type of diabetes encountered and to analyze the relationship between VD deficiency and diabetes complications. Methods: An observational study was conducted between May 2019 and May 2020 in French Guiana, based on data from the CODIAM study (Diabetes Cohort in French Amazonia), describing the characteristics of patients with diabetes mellitus. Among 600 patients enrolled with diabetes, 361 had an available VD assay. Results: The mean 25(OH)VD (hydroxycalciferol) level was 27.9 ng/mL. The level of VD was inversely proportional to the HbA1c (glycated hemoglobin) level. Patients with angina pectoris had a greater proportion of deficiencies VD < 20 ng/mL than those without angina. By contrast, patients with retinopathy had higher vitamin D concentrations than those without retinopathy. There was no association between vitamin D and arteriopathy, stroke, nephropathy and polyneuropathy. VD deficiency was more frequent in women, and in patients with a high school education. Conclusion: The prevalence of VD deficiency was high in patients with diabetes in French Guiana, emphasizing the importance of VD supplementation.
Collapse
Affiliation(s)
- Elise Girard
- Cayenne Hospital Center, Department of Endocrinology and Metabolic Diseases, 97306 Cayenne, French Guiana; (E.G.); (J.B.-K.); (M.M.); (R.B.); (L.T.); (D.O.); (J.M.A.)
| | - Mathieu Nacher
- Clinical Investigation Center Antilles French Guiana (CIC INSERM 1424), Cayenne Hospital Center, 97306 Cayenne, French Guiana; (M.N.); (A.F.); (A.A.)
| | - John Bukasa-Kakamba
- Cayenne Hospital Center, Department of Endocrinology and Metabolic Diseases, 97306 Cayenne, French Guiana; (E.G.); (J.B.-K.); (M.M.); (R.B.); (L.T.); (D.O.); (J.M.A.)
| | - Aniza Fahrasmane
- Clinical Investigation Center Antilles French Guiana (CIC INSERM 1424), Cayenne Hospital Center, 97306 Cayenne, French Guiana; (M.N.); (A.F.); (A.A.)
| | - Antoine Adenis
- Clinical Investigation Center Antilles French Guiana (CIC INSERM 1424), Cayenne Hospital Center, 97306 Cayenne, French Guiana; (M.N.); (A.F.); (A.A.)
| | - Mickael Massicard
- Cayenne Hospital Center, Department of Endocrinology and Metabolic Diseases, 97306 Cayenne, French Guiana; (E.G.); (J.B.-K.); (M.M.); (R.B.); (L.T.); (D.O.); (J.M.A.)
| | - Kinan Drak Alsibai
- Department of Pathology and Center of Biological Resources (CRB Amazonie), Cayenne Hospital Center, 97306 Cayenne, French Guiana;
| | - Bertrand De Toffol
- Department of Neurology Cayenne Hospital Center, 97306 Cayenne, French Guiana;
| | - Raissa Bekima
- Cayenne Hospital Center, Department of Endocrinology and Metabolic Diseases, 97306 Cayenne, French Guiana; (E.G.); (J.B.-K.); (M.M.); (R.B.); (L.T.); (D.O.); (J.M.A.)
| | - Liliane Thelusme
- Cayenne Hospital Center, Department of Endocrinology and Metabolic Diseases, 97306 Cayenne, French Guiana; (E.G.); (J.B.-K.); (M.M.); (R.B.); (L.T.); (D.O.); (J.M.A.)
| | - Diana Okambabelle
- Cayenne Hospital Center, Department of Endocrinology and Metabolic Diseases, 97306 Cayenne, French Guiana; (E.G.); (J.B.-K.); (M.M.); (R.B.); (L.T.); (D.O.); (J.M.A.)
| | - Magalie Demar
- Laboratory of Parasitology-Mycology (LHUPM), Cayenne Hospital Center, 97306 Cayenne, French Guiana;
- EA3593, Amazon Ecosystems and Tropical Diseases, University of Guiana, 97300 Cayenne, French Guiana
| | - Jean M. Aurelus
- Cayenne Hospital Center, Department of Endocrinology and Metabolic Diseases, 97306 Cayenne, French Guiana; (E.G.); (J.B.-K.); (M.M.); (R.B.); (L.T.); (D.O.); (J.M.A.)
| | - Nadia Sabbah
- Cayenne Hospital Center, Department of Endocrinology and Metabolic Diseases, 97306 Cayenne, French Guiana; (E.G.); (J.B.-K.); (M.M.); (R.B.); (L.T.); (D.O.); (J.M.A.)
- Clinical Investigation Center Antilles French Guiana (CIC INSERM 1424), Cayenne Hospital Center, 97306 Cayenne, French Guiana; (M.N.); (A.F.); (A.A.)
- Correspondence: ; Tel.: +594-594395276; Fax: +594-594394805
| |
Collapse
|
|
2
|
Elshebiny A, AlHewishel MA, Al Ghadeer HA, Alosaif N, Al Furaikh BF, ALHejji MS, Alsahaf HAA. Correlation of 25-Hydroxyvitamin D and Serum Lipid Levels Among Patients With Type 2 Diabetes. Cureus 2021; 13:e19667. [PMID: 34956773 PMCID: PMC8675586 DOI: 10.7759/cureus.19667] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/17/2021] [Indexed: 12/03/2022] Open
Abstract
Introduction Type 2 diabetes mellitus (T2DM) is a well-known health care problem. The is a growing interest in the role of vitamin D in metabolism including glucose and lipid metabolism. This study aims to investigate the possible association between 25-hydroxyvitamin D levels and serum lipid levels among patients with T2DM. Method A cross-sectional study was done at the King Faisal University Health Care Center in the Eastern Region of Saudi Arabia. Ethical approval was obtained from the Ethics and Research Committee at the College of Medicine, King Faisal University. We obtained the clinical and laboratory data of patients with T2DM by searching the electronic files of patients attending the center during the period between 2014 and 2021. Data collected included age, gender, nationality, vitamin D levels, HbA1c, and lipid levels. The chi-square and independent sample t-tests were applied when appropriate, for comparisons between groups to determine significance. A P-value of less than 0.05 was considered statistically significant. Result The study included 191 diabetic patients, 137 (71.7%) from Saudi Arabia, and 54 (28.3%) from other countries. Patient ages ranged from 21 to 100 years with a mean age of 56.2 ± 11.8 years. Cholesterol levels were observed to be high among 61 (32.3%) patients. Considering vitamin D, the average level among male patients was 26.526 ng/ml compared to 26 ng/ml% among females (P = 0.742). Conclusion Further long-term and more comprehensive randomized controlled trials are needed to make a firmer conclusion and stronger evidence on this beneficial role of vitamin D treatment on T2DM.
Collapse
Affiliation(s)
- Ahmed Elshebiny
- Internal Medicine, Diabetes and Endocrinology, Faculty of Medicine, Menoufia University, Shibin El Kom, EGY
- Internal Medicine, Diabetes and Endocrinology, King Faisal University, Al Hofuf, SAU
| | | | | | - Noor Alosaif
- College of Medicine, King Faisal University, Al Hofuf, SAU
| | | | - Muntaher S ALHejji
- Psychiatry and Behavioral Sciences, King Faisal University, Al Hofuf, SAU
| | | |
Collapse
|
|
3
|
Pokhrel S, Giri N, Pokhrel R, Pardhe BD, Lamichhane A, Chaudhary A, Bhatt MP. Vitamin D deficiency and cardiovascular risk in type 2 diabetes population. Open Life Sci 2021; 16:464-474. [PMID: 34017921 PMCID: PMC8114957 DOI: 10.1515/biol-2021-0050] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 04/09/2021] [Accepted: 04/13/2021] [Indexed: 11/28/2022] Open
Abstract
This study aims to assess vitamin D deficiency-induced dyslipidemia and cardiovascular disease (CVD) risk in poor glycemic control among type 2 diabetes mellitus (T2DM) patients. This study was carried out among 455 T2DM patients involving poor glycemic control (n = 247) and good glycemic control (n = 208). Fasting plasma glucose (FPG) and HbA1c were measured to assess glycemic control. Cardiac risk ratio, atherogenic index plasma, and atherogenic coefficient were calculated to assess and compare the CVD risk in different groups. Patients with poor control had a significantly higher level of total cholesterol (TC), triglyceride (TG), and non-high-density lipoprotein lipase cholesterol (non-HDL-C), atherogenic variables, and lower level of high-density lipoprotein lipase cholesterol (HDL-C) as compared to patients with good glycemic control. We also observed significant negative correlation of vitamin D with lipid markers and atherogenic variables in poor glycemic control diabetic population. The serum vitamin D levels were inversely associated with HbA1c, FPG, TG, TC, and non-HDL-C. Furthermore, hypercholesterolemia, hypertriglyceridemia, and elevated non-HDL-C were the independent risks in hypovitaminosis D population. Vitamin D deficiency in poor glycemic control is likely to develop dyslipidemia as compared to vitamin D insufficient and sufficient groups. Thus, vitamin D supplementation and an increase in exposure to sunlight may reduce the risk of cardiovascular complications in diabetes.
Collapse
Affiliation(s)
- Sushant Pokhrel
- Department of Laboratory Medicine, Manmohan Memorial Institute of Health Sciences, P. O. Box No. 15201, Kathmandu, Nepal
- Department of Genetics, National academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal
| | - Nisha Giri
- Department of Laboratory Medicine, Manmohan Memorial Institute of Health Sciences, P. O. Box No. 15201, Kathmandu, Nepal
| | - Rakesh Pokhrel
- Department of Biochemistry, Institute of Medicine, Maharajgunj Medical Campus, Kathmandu, Nepal
| | - Bashu Dev Pardhe
- Department of Life Science and Biochemical Engineering, Sun Moon University, Asan-Si, Chumgnam, South Korea
| | - Anit Lamichhane
- Department of Laboratory Medicine, Manmohan Memorial Institute of Health Sciences, P. O. Box No. 15201, Kathmandu, Nepal
| | - Abhisek Chaudhary
- Department of Clinical Pathology, Modern Diagnostic Laboratory and Research Center, Kathmandu, Nepal
| | - Mahendra Prasad Bhatt
- Department of Laboratory Medicine, Manmohan Memorial Institute of Health Sciences, P. O. Box No. 15201, Kathmandu, Nepal
| |
Collapse
|
|
4
|
Vitamin D as a Potential Therapy for Multiple Sclerosis: Where Are We? Int J Mol Sci 2020; 21:ijms21093102. [PMID: 32354174 PMCID: PMC7247155 DOI: 10.3390/ijms21093102] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 04/27/2020] [Accepted: 04/27/2020] [Indexed: 02/06/2023] Open
Abstract
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system and is caused by an aberrant immune response to myelin sheath. Disease-modifying medications, which mainly aim to suppress such aberrant immune response, have significantly improved MS treatment. However, the disease severity continues to worsen. In contrast, progressively more data suggest that 1,25-dihydroxyvitamin D or 1,25(OH)2D, i.e., the active vitamin D, suppresses the differentiation of potentially pathogenic T cells associated with MS, enhances the differentiation of regulatory T cells that suppress the pathogenic T cells, and promotes remyelination. These novel 1,25(OH)2D functions have encouraged investigators to develop vitamin D as a potential therapy for MS. However, because of the hypercalcemia that is associated with high 1,25(OH)2D concentrations, supplementation of native vitamin D has been a major focus in clinical trials for the treatment of MS, but such trials have produced mixed data. In this article, we will review current progress in the supplementation of different vitamin D forms for the treatment of experimental autoimmune encephalomyelitis (i.e., an MS animal model) as well as MS. Furthermore, we will review alternative strategies that our laboratory and others are pursuing in an attempt to circumvent the hurdles that are hampering the effective use of vitamin D as a potential therapy for MS.
Collapse
|